Summary

This report contains market size and forecasts of Specific Antiviral Drugs for COVID-19 in China, including the following market information:
China Specific Antiviral Drugs for COVID-19 Market Revenue, 2016-2021, 2022-2027, ($ millions)
China top five Specific Antiviral Drugs for COVID-19 companies in 2020 (%)
The global Specific Antiviral Drugs for COVID-19 market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.
The China Specific Antiviral Drugs for COVID-19 market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Specific Antiviral Drugs for COVID-19 Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China Specific Antiviral Drugs for COVID-19 Market, By Type, 2016-2021, 2022-2027 ($ Millions)
China Specific Antiviral Drugs for COVID-19 Market Segment Percentages, By Type, 2020 (%)
Tablet
Injection

China Specific Antiviral Drugs for COVID-19 Market, By Application, 2016-2021, 2022-2027 ($ Millions)
China Specific Antiviral Drugs for COVID-19 Market Segment Percentages, By Application, 2020 (%)
Mild Symptom Patient
Critically Ill Patient

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Specific Antiviral Drugs for COVID-19 revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies Specific Antiviral Drugs for COVID-19 revenues share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Novartis
Shanghai Zhongxisanwei
Teva
Zydus Cadila
Mylan
Apotex
Advanz Pharma
Sun Pharma
Kyung Poong
Ipca Laboratories
Hanlim Pharmaceutical
Bristol Laboratories
Bayer
Rising Pharmaceutical
Shanghai Pharma
Sichuan Sunny Hope
Guangzhou Baiyunshan Guanghua Pharmaceutical
CSPC Group
KPC Group
Jinghua Pharmaceutical Group
Zhongsheng Pharma
North China Pharmaceutical Group

ページTOPに戻る

Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Specific Antiviral Drugs for COVID-19 Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 China Specific Antiviral Drugs for COVID-19 Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year

2 China Specific Antiviral Drugs for COVID-19 Overall Market Size
2.1 China Specific Antiviral Drugs for COVID-19 Market Size: 2021 VS 2027
2.2 China Specific Antiviral Drugs for COVID-19 Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints

3 Company Landscape
3.1 Top Specific Antiviral Drugs for COVID-19 Players in China Market
3.2 Top China Specific Antiviral Drugs for COVID-19 Companies Ranked by Revenue
3.3 China Specific Antiviral Drugs for COVID-19 Revenue by Companies
3.4 Top 3 and Top 5 Specific Antiviral Drugs for COVID-19 Companies in China Market, by Revenue in 2020
3.5 Companies Specific Antiviral Drugs for COVID-19 Product Type
3.6 Tier 1, Tier 2 and Tier 3 Specific Antiviral Drugs for COVID-19 Players in China Market
3.6.1 List of Tier 1 Specific Antiviral Drugs for COVID-19 Companies in China
3.6.2 List of Tier 2 and Tier 3 Specific Antiviral Drugs for COVID-19 Companies in China

4 Sights by Type
4.1 Overview
4.1.1 By Type - China Specific Antiviral Drugs for COVID-19 Market Size Markets, 2021 & 2027
4.1.2 Tablet
4.1.3 Injection
4.2 By Type - China Specific Antiviral Drugs for COVID-19 Revenue & Forecasts
4.2.1 By Type - China Specific Antiviral Drugs for COVID-19 Revenue, 2016-2021
4.2.2 By Type - China Specific Antiviral Drugs for COVID-19 Revenue, 2022-2027
4.2.3 By Type - China Specific Antiviral Drugs for COVID-19 Revenue Market Share, 2016-2027

5 Sights by Application
5.1 Overview
5.1.1 By Application - China Specific Antiviral Drugs for COVID-19 Market Size, 2021 & 2027
5.1.2 Mild Symptom Patient
5.1.3 Critically Ill Patient
5.2 By Application - China Specific Antiviral Drugs for COVID-19 Revenue & Forecasts
5.2.1 By Application - China Specific Antiviral Drugs for COVID-19 Revenue, 2016-2021
5.2.2 By Application - China Specific Antiviral Drugs for COVID-19 Revenue, 2022-2027
5.2.3 By Application - China Specific Antiviral Drugs for COVID-19 Revenue Market Share, 2016-2027

6 Specific Antiviral Drugs for COVID-19 Companies Profiles
6.1 Sanofi
6.1.1 Sanofi Company Details
6.1.2 Sanofi Business Overview
6.1.3 Sanofi Specific Antiviral Drugs for COVID-19 Introduction
6.1.4 Sanofi Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.1.5 Sanofi Recent Developments
6.2 Novartis
6.2.1 Novartis Company Details
6.2.2 Novartis Business Overview
6.2.3 Novartis Specific Antiviral Drugs for COVID-19 Introduction
6.2.4 Novartis Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.2.5 Novartis Recent Developments
6.3 Shanghai Zhongxisanwei
6.3.1 Shanghai Zhongxisanwei Company Details
6.3.2 Shanghai Zhongxisanwei Business Overview
6.3.3 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Introduction
6.3.4 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.3.5 Shanghai Zhongxisanwei Recent Developments
6.4 Teva
6.4.1 Teva Company Details
6.4.2 Teva Business Overview
6.4.3 Teva Specific Antiviral Drugs for COVID-19 Introduction
6.4.4 Teva Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.4.5 Teva Recent Developments
6.5 Zydus Cadila
6.5.1 Zydus Cadila Company Details
6.5.2 Zydus Cadila Business Overview
6.5.3 Zydus Cadila Specific Antiviral Drugs for COVID-19 Introduction
6.5.4 Zydus Cadila Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.5.5 Zydus Cadila Recent Developments
6.6 Mylan
6.6.1 Mylan Company Details
6.6.2 Mylan Business Overview
6.6.3 Mylan Specific Antiviral Drugs for COVID-19 Introduction
6.6.4 Mylan Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.6.5 Mylan Recent Developments
6.7 Apotex
6.7.1 Apotex Company Details
6.7.2 Apotex Business Overview
6.7.3 Apotex Specific Antiviral Drugs for COVID-19 Introduction
6.7.4 Apotex Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.7.5 Apotex Recent Developments
6.8 Advanz Pharma
6.8.1 Advanz Pharma Company Details
6.8.2 Advanz Pharma Business Overview
6.8.3 Advanz Pharma Specific Antiviral Drugs for COVID-19 Introduction
6.8.4 Advanz Pharma Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.8.5 Advanz Pharma Recent Developments
6.9 Sun Pharma
6.9.1 Sun Pharma Company Details
6.9.2 Sun Pharma Business Overview
6.9.3 Sun Pharma Specific Antiviral Drugs for COVID-19 Introduction
6.9.4 Sun Pharma Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.9.5 Sun Pharma Recent Developments
6.10 Kyung Poong
6.10.1 Kyung Poong Company Details
6.10.2 Kyung Poong Business Overview
6.10.3 Kyung Poong Specific Antiviral Drugs for COVID-19 Introduction
6.10.4 Kyung Poong Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.10.5 Kyung Poong Recent Developments
6.11 Ipca Laboratories
6.11.1 Ipca Laboratories Company Details
6.11.2 Ipca Laboratories Business Overview
6.11.3 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Introduction
6.11.4 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.11.5 Ipca Laboratories Recent Developments
6.12 Hanlim Pharmaceutical
6.12.1 Hanlim Pharmaceutical Company Details
6.12.2 Hanlim Pharmaceutical Business Overview
6.12.3 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction
6.12.4 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.12.5 Hanlim Pharmaceutical Recent Developments
6.13 Bristol Laboratories
6.13.1 Bristol Laboratories Company Details
6.13.2 Bristol Laboratories Business Overview
6.13.3 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Introduction
6.13.4 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.13.5 Bristol Laboratories Recent Developments
6.14 Bayer
6.14.1 Bayer Company Details
6.14.2 Bayer Business Overview
6.14.3 Bayer Specific Antiviral Drugs for COVID-19 Introduction
6.14.4 Bayer Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.14.5 Bayer Recent Developments
6.15 Rising Pharmaceutical
6.15.1 Rising Pharmaceutical Company Details
6.15.2 Rising Pharmaceutical Business Overview
6.15.3 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction
6.15.4 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.15.5 Rising Pharmaceutical Recent Developments
6.16 Shanghai Pharma
6.16.1 Shanghai Pharma Company Details
6.16.2 Shanghai Pharma Business Overview
6.16.3 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Introduction
6.16.4 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.16.5 Shanghai Pharma Recent Developments
6.17 Sichuan Sunny Hope
6.17.1 Sichuan Sunny Hope Company Details
6.17.2 Sichuan Sunny Hope Business Overview
6.17.3 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Introduction
6.17.4 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.17.5 Sichuan Sunny Hope Recent Developments
6.18 Guangzhou Baiyunshan Guanghua Pharmaceutical
6.18.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Company Details
6.18.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Business Overview
6.18.3 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction
6.18.4 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.18.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments
6.19 CSPC Group
6.19.1 CSPC Group Company Details
6.19.2 CSPC Group Business Overview
6.19.3 CSPC Group Specific Antiviral Drugs for COVID-19 Introduction
6.19.4 CSPC Group Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.19.5 CSPC Group Recent Developments
6.20 KPC Group
6.20.1 KPC Group Company Details
6.20.2 KPC Group Business Overview
6.20.3 KPC Group Specific Antiviral Drugs for COVID-19 Introduction
6.20.4 KPC Group Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.20.5 KPC Group Recent Developments
6.21 Jinghua Pharmaceutical Group
6.21.1 Jinghua Pharmaceutical Group Company Details
6.21.2 Jinghua Pharmaceutical Group Business Overview
6.21.3 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Introduction
6.21.4 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.21.5 Jinghua Pharmaceutical Group Recent Developments
6.22 Zhongsheng Pharma
6.22.1 Zhongsheng Pharma Company Details
6.22.2 Zhongsheng Pharma Business Overview
6.22.3 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Introduction
6.22.4 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.22.5 Zhongsheng Pharma Recent Developments
6.23 North China Pharmaceutical Group
6.23.1 North China Pharmaceutical Group Company Details
6.23.2 North China Pharmaceutical Group Business Overview
6.23.3 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Introduction
6.23.4 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Revenue in China Market (2016-2021)
6.23.5 North China Pharmaceutical Group Recent Developments

7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer